RDY · Dr Reddy's Laboratories
AI read · Neutral
The AI's read
The decline came mainly from lower lenalidomide sales, while the underlying base business grew by double digits. Gross profit margin also fell from a year earlier, even as it improved from the prior quarter. New launches and a planned semaglutide relaunch may support later growth, but they do not erase the mixed results from this quarter.